KR20230015320A - 감염성 질환의 치료에서의 부실라민의 용도 - Google Patents

감염성 질환의 치료에서의 부실라민의 용도 Download PDF

Info

Publication number
KR20230015320A
KR20230015320A KR1020227036230A KR20227036230A KR20230015320A KR 20230015320 A KR20230015320 A KR 20230015320A KR 1020227036230 A KR1020227036230 A KR 1020227036230A KR 20227036230 A KR20227036230 A KR 20227036230A KR 20230015320 A KR20230015320 A KR 20230015320A
Authority
KR
South Korea
Prior art keywords
effective amount
therapeutically effective
day
disease
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020227036230A
Other languages
English (en)
Korean (ko)
Inventor
파비오 안드레아 치아넬리
마이클 프랭크
Original Assignee
리바이브 테라퓨틱스 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 리바이브 테라퓨틱스 엘티디. filed Critical 리바이브 테라퓨틱스 엘티디.
Publication of KR20230015320A publication Critical patent/KR20230015320A/ko
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020227036230A 2020-03-19 2021-03-16 감염성 질환의 치료에서의 부실라민의 용도 Withdrawn KR20230015320A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991996P 2020-03-19 2020-03-19
US62/991,996 2020-03-19
PCT/CA2021/050350 WO2021184115A1 (en) 2020-03-19 2021-03-16 Use of bucillamine in the treatment of infectious diseases

Publications (1)

Publication Number Publication Date
KR20230015320A true KR20230015320A (ko) 2023-01-31

Family

ID=77767915

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036230A Withdrawn KR20230015320A (ko) 2020-03-19 2021-03-16 감염성 질환의 치료에서의 부실라민의 용도

Country Status (5)

Country Link
US (1) US20230172884A1 (https=)
EP (1) EP4121035A4 (https=)
JP (1) JP2023518430A (https=)
KR (1) KR20230015320A (https=)
WO (1) WO2021184115A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3183146A1 (en) * 2020-05-13 2021-11-18 The Regents Of The University Of California Thiol-containing compounds for use in treating coronavirus

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025393A (en) * 1995-09-25 2000-02-15 Santen Pharmaceutical Co., Ltd. Method for treatment of inflammatory intestinal diseases
WO2010014953A1 (en) * 2008-08-01 2010-02-04 The Regents Of The University Of Colorado, A Body Corporate Prolonged administration of a dithiol anti-oxidant protects against ventricular remodeling
WO2011094598A2 (en) * 2010-01-28 2011-08-04 The Johns Hopkins University Compositions and methods for reversing corticosteroid resistance or treating respiratory infections
US20110218241A1 (en) * 2010-03-06 2011-09-08 Cacao Bio-Technologies, Llc Antiviral epicatechins, epicatechin oligomers, or thiolated epicatechins from theobroma cacao for treatment of genital warts
GB201012889D0 (en) * 2010-08-02 2010-09-15 Univ Leuven Kath Antiviral activity of novel bicyclic heterocycles
US9238018B2 (en) * 2012-11-20 2016-01-19 Revive Therapeutics Inc. Use of bucillamine in the treatment of gout
CA3017797A1 (en) * 2016-03-17 2017-09-21 Thiogenesis Therapeutics, Inc. Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders

Also Published As

Publication number Publication date
US20230172884A1 (en) 2023-06-08
EP4121035A1 (en) 2023-01-25
JP2023518430A (ja) 2023-05-01
WO2021184115A1 (en) 2021-09-23
EP4121035A4 (en) 2024-04-24
CA3172170A1 (en) 2021-09-23

Similar Documents

Publication Publication Date Title
EP0820281B1 (en) A pharmaceutical composition containing n-chlorophenylcarbamates and n-chlorophenylthiocarbamates for inhibiting the growth of viruses
WO2022218958A1 (en) Combination comprising everolimus and amcenestrant
JP2004516257A (ja) 糖尿病性神経障害の治療に対する組成物及びその方法
FR2809310A1 (fr) Utilisation de derives de biguanide pour fabriquer un medicament ayant un effet cicatrisant
EP0629400B1 (en) Idebenone compositions for treating Alzheimer's disease
US9149514B2 (en) Composition and method for treating papilloma virus and equine sarcoids
BG60400B2 (bg) Синергитични фармацевтични препарати, тяхното получаване и употребата им
KR20230015320A (ko) 감염성 질환의 치료에서의 부실라민의 용도
UA123780C2 (uk) Лікування екземи кистей
JP2004091473A (ja) 色素沈着改善治療薬
CA3172170C (en) Use of bucillamine in the treatment of infectious diseases
RU2096034C1 (ru) Фармацевтическая композиция, индуцирующая биосинтез глутатиона, активность глутатионтрансферазы и оказывающая антитоксическое, радиопротекторное и антигипоксическое действие, и способы лечения, профилактики и защиты с ее использованием
EP1970061A1 (en) Medicinal agent for treating viral infections
EP4159214B1 (en) Composition for treating, improving, and/or preventing progression of bovine papillomatosis caused by bovine papillomavirus
CN106983741A (zh) 氰基丙烯酸酯类化合物在治疗人畜真菌性感染疾病上的应用
US20170258746A1 (en) Acetic acid/thymol compositions and their use in the treatment of onychomycosis
US3074848A (en) 2-hydroxy-5,2'-dichloro-4'-nitrobenzanilide for combating tapeworms
KR950702413A (ko) 암치료에 2-(4-(4-클로로페닐)시클로헥실)-3-히드록시-1, 4-나프토퀴논을 사용하는 방법(use of 2-(4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone for the treatment of cancer)
CH630803A5 (en) Medicinal preparations, for the treatment of hypercholesterolaemia in particular
HUT55630A (en) Process for producing pharmaceutical compositions for lowering trigliceride and cholesterol level and highering level of lipoprotheines of high density
CN104147006A (zh) 盐酸去亚甲基小檗碱在制备预防和/或治疗异烟肼致药源性肝损伤药物中的应用
CN114401724B (zh) 一种降糖药物组合物
JP2002265354A (ja) 抗ピロリ菌剤組成物
CN110891574A (zh) 用于预防和/或治疗肝细胞癌的美格列明
JP2876224B2 (ja) 新規美白剤

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PC1203 Withdrawal of no request for examination

St.27 status event code: N-1-6-B10-B12-nap-PC1203